The efficacy of nucleoside analogs against JC virus multiplication in a persistently infected human fetal brain cell line.
The effectiveness of nucleoside analogs in blocking viral multiplication was evaluated using an immortalized human neuroglial cell line capable of sustaining a persistent JCV infection, SVG-JC. Results from in situ DNA hybridization and hemagglutination assays performed on drug treated cultures were used as a measure of viral DNA replication and multiplication, respectively. Of the three drugs tested, Ara-C (cytosine arabinoside), AZT (3'-azido-3'-deoxythymidine), and cidofovir (S)-1-[3-hydroxy-2-(phosphonylmethoxypropyl] cytosine), only Ara-C showed a significant effect in decreasing active JCV replication and multiplication. In vitro data, using different cell types and virus strains have shown that specific drugs can indeed modulate viral infection. However, such modulation has not previously been demonstrated in those cells of the CNS which are specifically targeted by JCV. The SVG-JC cells represent a unique system with which further studies can be conducted on the effects of drugs on brain derived cells that are susceptible to viral infection.
Hou
J
J
Laboratory of Molecular Medicine and Neuroscience, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892, USA.
Major
E O
EO
D019380:Anti-HIV Agents / Q000494:pharmacology; D000998:Antiviral Agents / Q000494:pharmacology; D001921:Brain / Q000166:cytology; D002478:Cells, Cultured; D000077404:Cidofovir; D003561:Cytarabine / Q000494:pharmacology; D003596:Cytosine / Q000031:analogs & derivatives / Q000494:pharmacology; D004279:DNA, Viral / Q000032:analysis; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005333:Fetus / Q000166:cytology; D006801:Humans; D007577:JC Virus / Q000235:genetics / Q000254:growth & development*; D009474:Neurons / Q000166:cytology / Q000821:virology*; D009705:Nucleosides / Q000494:pharmacology*; D063065:Organophosphonates; D009943:Organophosphorus Compounds / Q000494:pharmacology; D030361:Papillomavirus Infections / Q000188:drug therapy*; D019772:Topotecan / Q000494:pharmacology; D014412:Tumor Virus Infections / Q000188:drug therapy*; D014779:Virus Replication / Q000187:drug effects; D015215:Zidovudine / Q000494:pharmacology
D019380:Anti-HIV Agents; D000998:Antiviral Agents; D004279:DNA, Viral; D004791:Enzyme Inhibitors; D009705:Nucleosides; D063065:Organophosphonates; D009943:Organophosphorus Compounds; D003561:Cytarabine; D015215:Zidovudine; D019772:Topotecan; D003596:Cytosine; D000077404:Cidofovir